TY - JOUR
T1 - Advances and future directions in the targeting of HER2-positive breast cancer
T2 - Implications for the future
AU - Subbiah, Ishwaria M.
AU - Gonzalez-Angulo, Ana Maria
N1 - Funding Information:
This work was supported in part by National Cancer Institute 1K23CA121994 (AMG) ASCO Career Development Award (AMG), Komen for the Cure Catalystic Award KG090341 (AMG), American Cancer Society Research Scholar Grant 121329-RSG-11-187-01-TBG (AMG), National Cancer Institute through The University of Texas MD Anderson’s Cancer Center Support Grant (P30 CA016672).
PY - 2014/3
Y1 - 2014/3
N2 - The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.
AB - The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.
KW - HER2-positive breast cancer
KW - Immunotherapy
KW - PI3K signaling
KW - Pertuzumab
KW - T-DM1
KW - Trastuzumab resistance
UR - http://www.scopus.com/inward/record.url?scp=84894660263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894660263&partnerID=8YFLogxK
U2 - 10.1007/s11864-013-0262-4
DO - 10.1007/s11864-013-0262-4
M3 - Article
C2 - 24323591
AN - SCOPUS:84894660263
SN - 1527-2729
VL - 15
SP - 41
EP - 54
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 1
ER -